---
figid: PMC8113755__fcell-09-671022-g001
figtitle: WNT plasma membrane signaling in PDAC
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC8113755
filename: fcell-09-671022-g001.jpg
figlink: pmc/articles/PMC8113755/figure/F1/
number: F1
caption: WNT plasma membrane signaling in PDAC. (Left panel) In the absence of FZD-LRP5/6
  signaling (lack of WNT ligand and/or inhibition by extracellular DKKs or SFRPs),
  β-catenin is targeted for degradation. GSK3β activity also impinges other signaling
  pathways and controls ubiquitin-mediated degradation of proteins. (Right panel)
  Augmented by RNF43 mutations or RSPO inhibition of RNF43, WNT ligand signaling re-localizes
  and inactivates the destruction complex to stabilize β-catenin, increasing its nuclear
  translocation and co-transcriptional activity. GSK3β sequestration in multivesicular
  bodies (MVB) prevents substrate phosphorylation, promoting WNT-STOP, WNT-MTOR, and
  further pathway crosstalk (i.e., de-repression of MAPK/ERK). Thus, upstream WNT
  pathway inhibitors (PORCN inhibitors, FZD receptor blockers, and FZD decoy receptors)
  mediate additional actions divergent from downstream WNT pathway inhibitors targeting
  β-catenin in the nucleus (i.e., PRI-724). Created with BioRender.com.
papertitle: WNT Ligand Dependencies in Pancreatic Cancer.
reftext: Kristina Y. Aguilera, et al. Front Cell Dev Biol. 2021;9:671022.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9621233
figid_alias: PMC8113755__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC8113755__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8113755__fcell-09-671022-g001.html
  '@type': Dataset
  description: WNT plasma membrane signaling in PDAC. (Left panel) In the absence
    of FZD-LRP5/6 signaling (lack of WNT ligand and/or inhibition by extracellular
    DKKs or SFRPs), β-catenin is targeted for degradation. GSK3β activity also impinges
    other signaling pathways and controls ubiquitin-mediated degradation of proteins.
    (Right panel) Augmented by RNF43 mutations or RSPO inhibition of RNF43, WNT ligand
    signaling re-localizes and inactivates the destruction complex to stabilize β-catenin,
    increasing its nuclear translocation and co-transcriptional activity. GSK3β sequestration
    in multivesicular bodies (MVB) prevents substrate phosphorylation, promoting WNT-STOP,
    WNT-MTOR, and further pathway crosstalk (i.e., de-repression of MAPK/ERK). Thus,
    upstream WNT pathway inhibitors (PORCN inhibitors, FZD receptor blockers, and
    FZD decoy receptors) mediate additional actions divergent from downstream WNT
    pathway inhibitors targeting β-catenin in the nucleus (i.e., PRI-724). Created
    with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PORCN
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - RSPO1
  - RNF43
  - LGR4
  - LGR5
  - RNU6-664P
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - CSNK1A1
  - AXIN1
  - AXIN2
  - APC
  - PROC
  - TRIM31
  - CAT
  - CRAT
  - GLYAT
  - MYC
  - GET4
  - CTNNB1
  - GSK3B
  - MTOR
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - CP
  - TSC1
  - CCL26
  - HNF4A
  - LRP6
  - LRP5
  - Porcn
  - Wnt7b
  - H2-Aa
  - Wnt2
  - Rnf43
  - Lgr4
  - Lgr5
  - Fzd5
  - Dvl1
  - Csnk1a1
  - Axin1
  - Apc
  - Trim31
  - Cat
  - cac
  - Mip
  - Trpv6
  - Glyat
  - Myc
  - Nol3
  - Get4
  - Ctnnb1
  - Gsk3b
  - Mtor
  - Crebbp
  - Pag1
  - Cytip
  - Cp
  - Tsc1
  - Lrp6
  - Lrp5
---
